@article{9570ba100deb446984a9f50977c7b019,
title = "Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma",
abstract = "We studied T-BiRD (thalidomide [Thalomid{\textregistered}], clarithromycin [Biaxin{\textregistered}], lenalidomide [Revlimid{\textregistered}] and dexamethasone) in symptomatic, newly diagnosed multiple myeloma. In 28-day cycles, patients received dexamethasone 40 mg/day on days 1, 8, 15, 22, clarithromycin 500 mg twice daily on days 1-28; lenalidomide 25 mg/day on days 1-21; and thalidomide 100 mg/day (50 mg/day on days 1-7 of cycle 1 only) on days 1-28. Twenty-six patients received a median of 6 cycles (range 0-41). Overall response rate (ORR) was 80% for the group and 100% in 11 patients who underwent autologous stem cell transplantation as part of first-line therapy. The 4-year overall survival rate was 74.9%, and the median progression-free survival was 35.6 months. Eight patients discontinued due to regimen toxicity. Grade 3 non hematologic toxicity affected 12 patients (46.2%). T-BiRD is a highly active regimen with potential toxicity limitations. ClinicalTrials.gov",
keywords = "Clarithromycin, Dexamethasone, Lenalidomide, Newly diagnosed multiple myeloma, Thalidomide",
author = "Mark, {Tomer M.} and Bowman, {Isaac A.} and Rossi, {Adriana C.} and Manan Shah and Melissa Rodriguez and Ryann Quinn and Pearse, {Roger N.} and Faiza Zafar and Karen Pekle and David Jayabalan and Scott Ely and Morton Coleman and Selina Chen-Kiang and Ruben Niesvizky",
note = "Funding Information: Celgene Corporation provided financial support for this study. The study was an investigator-initiated protocol. The protocol design, data collection, data analysis and interpretation, and choice of journal submission was performed independently of the sponsor. Medical writing support was funded by Celgene Corporation. Funding Information: Medical writing support was provided by Ryan Woodrow and Kate Unsworth of the Investigator-Initiated Research Writing Group (part of the KnowledgePoint360 Group) and was funded by Celgene Corporation. This investigator-initiated study was funded by the Celgene Corporation. This work was supported by a Clinical and Translational Science Center grant (CTSC GRANT UL1-RR024996). Publisher Copyright: {\textcopyright} 2014 Informa UK, Ltd.",
year = "2014",
month = dec,
day = "1",
doi = "10.3109/10428194.2014.896005",
language = "English (US)",
volume = "55",
pages = "2842--2849",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",
}